Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18
"Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A vaccine containing L1 capsid proteins from four types of HPV (ALPHAPAPILLOMAVIRUS), types 6, 11, 16 and 18 that is used to prevent infections from HUMAN PAPILLOMAVIRUSES of these subtypes.
Descriptor ID |
D000068857
|
MeSH Number(s) |
D20.215.894.899.498.500
|
Concept/Terms |
Human Papillomavirus Vaccine L1, Type 6,11,16,18- Human Papillomavirus Vaccine L1, Type 6,11,16,18
- HPV L1 Vaccine, Quadrivalent 6,11,16,18
|
Below are MeSH descriptors whose meaning is more general than "Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18".
Below are MeSH descriptors whose meaning is more specific than "Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18".
This graph shows the total number of publications written about "Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18" by people in this website by year, and whether "Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
Year | Major Topic | Minor Topic | Total |
---|
2009 | 0 | 1 | 1 | 2010 | 0 | 1 | 1 | 2011 | 0 | 2 | 2 | 2013 | 0 | 2 | 2 | 2014 | 0 | 2 | 2 | 2015 | 1 | 0 | 1 | 2017 | 2 | 0 | 2 | 2018 | 2 | 0 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18" by people in Profiles.
-
Cespedes MS, Kang M, Kojic EM, Umbleja T, Godfrey C, Webster-Cyriaque JY, Masih R, Firnhaber C, Grinsztejn B, Saah A, Cu-Uvin S, Aberg JA. Anogenital human papillomavirus virus DNA and sustained response to the quadrivalent HPV vaccine in women living with HIV-1. Papillomavirus Res. 2018 12; 6:15-21.
-
Kharbanda EO, Vazquez-Benitez G, Lipkind HS, Sheth SS, Zhu J, Naleway AL, Klein NP, Hechter R, Daley MF, Donahue JG, Jackson ML, Kawai AT, Sukumaran L, Nordin JD. Risk of Spontaneous Abortion After Inadvertent Human Papillomavirus Vaccination in Pregnancy. Obstet Gynecol. 2018 07; 132(1):35-44.
-
Lipkind HS, Vazquez-Benitez G, Nordin JD, Romitti PA, Naleway AL, Klein NP, Hechter RC, Jackson ML, Hambidge SJ, Lee GM, Sukumaran L, Kharbanda EO. Maternal and Infant Outcomes After Human Papillomavirus Vaccination in the Periconceptional Period or During Pregnancy. Obstet Gynecol. 2017 09; 130(3):599-608.
-
Levin MJ, Huang S, Moscicki AB, Song LY, Read JS, Meyer WA, Saah AJ, Richardson K, Weinberg A. Four-year persistence of type-specific immunity after quadrivalent human papillomavirus vaccination in HIV-infected children: Effect of a fourth dose of vaccine. Vaccine. 2017 03 23; 35(13):1712-1720.
-
Naleway AL, Crane B, Smith N, Daley MF, Donahue J, Gee J, Greene SK, Harrington T, Jackson LA, Klein NP, Tseng HF, Vellozzi C, Weintraub ES. Absence of venous thromboembolism risk following quadrivalent human papillomavirus vaccination, Vaccine Safety Datalink, 2008-2011. Vaccine. 2016 Jan 02; 34(1):167-71.
-
Kojic EM, Kang M, Cespedes MS, Umbleja T, Godfrey C, Allen RT, Firnhaber C, Grinsztejn B, Palefsky JM, Webster-Cyriaque JY, Saah A, Aberg JA, Cu-Uvin S. Immunogenicity and safety of the quadrivalent human papillomavirus vaccine in HIV-1-infected women. Clin Infect Dis. 2014 Jul 01; 59(1):127-35.
-
Einstein MH, Levin MJ, Chatterjee A, Chakhtoura N, Takacs P, Catteau G, Dessy FJ, Moris P, Lin L, Struyf F, Dubin G. Comparative humoral and cellular immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18-45 years: follow-up through Month 48 in a Phase III randomized study. Hum Vaccin Immunother. 2014; 10(12):3455-65.
-
Schmidt MA, Gold R, Kurosky SK, Daley MF, Irving SA, Gee J, Naleway AL. Uptake, coverage, and completion of quadrivalent human papillomavirus vaccine in the vaccine safety Datalink, July 2006-June 2011. J Adolesc Health. 2013 Nov; 53(5):637-41.
-
Chesson HW, Flagg EW, Koutsky L, Hsu K, Unger ER, Shlay JC, Kerndt P, Ghanem KG, Zenilman JM, Hagensee M, Weinstock H, Datta SD. Modeling the impact of quadrivalent HPV vaccination on the incidence of Pap test abnormalities in the United States. Vaccine. 2013 Jun 24; 31(29):3019-24.
-
Einstein MH, Baron M, Levin MJ, Chatterjee A, Fox B, Scholar S, Rosen J, Chakhtoura N, Meric D, Dessy FJ, Datta SK, Descamps D, Dubin G. Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/18 vaccine: follow-up from months 12-24 in a Phase III randomized study of healthy women aged 18-45 years. Hum Vaccin. 2011 Dec; 7(12):1343-58.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|